BRAF p.V600K
About
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) | BRAF p.V600K | Melanoma | Atezolizumab, Cobimetinib, Vemurafenib | |
| EMA (2) FDA (2) | BRAF p.V600K | Melanoma | Binimetinib, Encorafenib | |
| EMA (1) FDA (1) | BRAF p.V600K | Melanoma | Cobimetinib, Vemurafenib | |
| EMA (4) FDA (4) | BRAF p.V600K | Melanoma | Dabrafenib, Trametinib | |
| EMA (1) FDA (1) | BRAF p.V600K | Melanoma | Trametinib | |
| FDA (1) | BRAF p.V600K | Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease | Vemurafenib | |
| EMA (1) FDA (1) | BRAF p.V600K | Low-Grade Glioma, NOS | Tovorafenib | |
| EMA (2) | BRAF p.V600K | Non-Small Cell Lung Cancer | Dabrafenib, Trametinib | |
| EMA (1) | BRAF p.V600K | Melanoma | Dabrafenib | |
| EMA (1) | BRAF p.V600K | Melanoma | Vemurafenib |